The Interstitial Lung Disease (ILD) Treatment Market revealing steady growth driven by rising
prevalence, environmental risk factors, and increased diagnostic capacity. According to
IMR’s analysis, the global ILD treatment market, valued at approximately USD 1.10 billion
in 2023, is projected to reach USD 1.70 billion by 2032, growing at a compound annual
growth rate (CAGR) of ~4.97% over the forecast period.
This report (Report ID: 16091) offers a deep dive into market segmentation by diagnosis
type, disease subtype, treatment modality, route of administration, and geographies,
providing strategic insights for pharmaceutical companies, healthcare providers, and
investors
Quick Insights
 Market Size (2023): ~ USD 1.1 billion
 Forecast Market Size (2032): ~ USD 1.70 Billion
 Projected CAGR (2024–2032): ~ 4.97%
 Top Region (2023): North America
 Fastest-growing Region: Asia-Pacific, driven by asbestos-related ILD cases Leading
Disease Segment: Sarcoidosis is expected to dominate disease-type share
 Key Market Players: Merck Sharp & Dohme, Gilead, Bristol-Myers Squibb,
FibroGen, Liminal Biosciences, Boehringer Ingelheim, Roche, Galecto, J.B.
Chemicals & Pharmaceutical, Cipla, Glenmark Pharma.
What’s Driving the Market?
The ILD treatment market’s growth is underpinned by several key forces:
 Rising incidence of ILDs, especially in aging populations, combined with increasing
exposure to environmental risk factors such as air pollution and asbestos.
 Greater disease awareness and better access to advanced diagnostic tools, notably
high-resolution CT (HRCT) scans, enabling earlier detection and treatment.
Regulatory support and clinical research, especially for novel therapies, creating
more treatment options and expanding patient access.
 Epidemiological pressure in developing regions, particularly Asia-Pacific, where
asbestos-related ILD remains a serious challenge despite regulatory bans.
Where Are the Opportunities — and What Trends Are Emerging?
Could targeted biologics and diagnostics reshape ILD treatment?
As more molecular and precision therapies are developed, there is a growing opportunity to
tailor ILD treatment based on disease subtype (e.g., IPF vs. sarcoidosis), patient risk profile,
and progression rate. The rising uptake of HRCT diagnostics also supports this trend by
enabling more accurate stratification of patients for personalized therapies.
Is cost-efficiency finally within reach?
Treatment costs remain a major barrier, especially in regions with limited healthcare funding.
There is increasing pressure on manufacturers to not just innovate, but to deliver more costefficient therapies — potentially through biosimilars, repurposed drugs, or combination
regimens that reduce long-term hospitalization or oxygen therapy use.
Expert Commentary
“Our forecast underscores a clear but nuanced growth trajectory for ILD treatment,” said Dr.
Meera Joshi, Principal Consultant, Introspective Market Research. “While the overall
market is expanding steadily, the real inflection point will come when diagnostics,
particularly imaging, converge with next-generation biologics — enabling earlier intervention
and more personalized care. This is especially critical in high-burden regions such as AsiaPacific, where environmental factors like asbestos still drive disease prevalence.”
Regional and Segmentation Analysis
 North America currently holds the largest share due to robust healthcare
infrastructure and high disease burden, especially for idiopathic pulmonary fibrosis
(IPF).
 Europe follows, with persistent smoking rates and air pollution contributing to ILD
cases in key countries. Asia-Pacific is expected to record the fastest growth,
propelled by asbestos exposure, an aging population, and rising awareness.
On the diagnosis front, high-resolution CT imaging dominates, valued for its ability to
delineate lung lesions and guide therapy. In disease subtypes, sarcoidosis is projected to lead
market share, especially in populations of African and Scandinavian ancestry. In treatment
modalities, medications (including antifibrotics and immunosuppressants), pulmonary
rehabilitation, oxygen therapy, and surgery are all key segments. The route of
administration is diversified among oral, injectable, and other forms.
Cutting-Edge Developments from Leading Players
 In Boehringer Ingelheim’s pipeline, BI 1015550, a PDE4B inhibitor, has received
breakthrough therapy designation from the FDA for idiopathic pulmonary fibrosis
(IPF), targeting both inflammation and fibrosis
 FibroGen’s pamrevlumab, which inhibits connective tissue growth factor (CTGF),
has also earned breakthrough designation in IPF, highlighting the momentum in antifibrotic novel therapies.
 Roche’s tocilizumab (Actemra/RoActemra) has secured FDA approval for systemic
sclerosis–associated ILD, marking the first biologic therapy for this indication.
Addressing Cost Pressures & Enhancing Affordability
Cost remains a critical challenge in ILD management. Long-term therapies such as
antifibrotics (e.g., pirfenidone, nintedanib) can impose significant financial burden. Key
strategies to improve cost-efficiency include:
 Development of biosimilars or generics to bring down drug costs.
 Repurposing existing drugs or exploring combination therapies to optimize efficacy
and reduce doses.
 Expansion of clinical trial participation in emerging markets, which could lower
development costs and improve access.
 Enhancing digital health and remote monitoring (e.g., tele-pulmonology) to reduce
hospital visits and associated costs.

Why This Matters
Patients living with ILD often face progressive, debilitating symptoms, and historically
limited therapeutic options. IMR’s research shows that as diagnostics improve and new
therapies reach the clinic, the ILD treatment landscape is shifting — companies have a real
opportunity to make a meaningful clinical and economic impact. For stakeholders, this is not
just a growth market, but a chance to address an unmet global health need.

Download & Connect

To explore detailed chapters — including segment-level forecasts, competitor heat maps,
and unmet needs analysis — you can access a free sample here:

Download Sample:- https://introspectivemarketresearch.com/request/16091
For a walkthrough of the full report, or to schedule a meeting with one of our consultants,
please request a demo or email us at info@introspectivemarketresearch.com.

About Introspective Market Research

Introspective Market Research (IMR) is a leading market intelligence firm specializing in
deep-dive analysis and data-driven insights across pharmaceutical, biotech, healthcare, and
life-sciences sectors. Our team of senior analysts and consultants works closely with
stakeholders — from global pharma to emerging biotech — to inform strategy, guide R&D,
and drive growth.